Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor

Inclusion Criteria: * Age between 18-79; * The patient must be able to give informed consent; * Patients can finish PET/CT scan without tranquilizers; * Patients with pathology-proven cancer or a tumor highly suspected to be malignant ; * Lesions can be measured and assessed at the RECIST 1.1 standard; * No chemotherapy, radiotherapy or immune/biologic therapy,or biopsy were allowed between the 18F-FDG and the 4-\[18F\]Fluoroglutamine PET/CT. Exclusion Criteria: * Pregnant or lactating patients; * Inability or refusal to have at least one peripheral intravenous line for intravenous access; * From assays obtained \<2 weeks prior to study enrollment（ULN：the upper limit of normal value ）:Bilirubin\>1.5\*ULN,AST/ALT \>2.5 \* ULN, Albumin\< 3 g/dl, GGT \> 2.5 x ULN if ALP\> 2.5 x ULN, Creatinine\>1.5\*ULN or creatinine clearance \<60ml/min； * Patients with a history of allergic reaction to this drugs or its analogues； * patients with poor compliance; * Acute major illness